China SXT PharmaceuticalsSXTC -7.48%26 PB Ratio is 0.09 as of Jun. 26, 2026, which is 47% below its 10-year median of 0.17. GuruFocus rates SXTC with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 99.35% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China SXT Pharmaceuticals PB Ratio Related Terms
China SXT Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China SXT Pharmaceuticals (SXTC) has a PB Ratio of 0.09 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China SXT Pharmaceuticals and its competitors. This is 47% below median its historical median of 0.17. Over the past decade, China SXT Pharmaceuticals' PB Ratio has ranged from 0.01 to 2.23. According to the industry distribution chart, China SXT Pharmaceuticals ranks #6 out of 922 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is China SXT Pharmaceuticals' PB Ratio too high?
China SXT Pharmaceuticals' current PB Ratio of 0.09 is 47% below median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.23. The Drug Manufacturers industry median PB Ratio is 1.86. China SXT Pharmaceuticals' value of 0.09 is 95.1% below this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #6 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' PB Ratio compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #6 out of 922 companies for PB Ratio. This places China SXT Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.86. China SXT Pharmaceuticals' value of 0.09 is 95.1% below this benchmark. Historically, China SXT Pharmaceuticals' own PB Ratio has ranged from 0.01 to 2.23 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 1.86, China SXT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current PB Ratio of 0.09 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current PB Ratio is 0.09, which is 47% below median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (SXTC) has a current PB Ratio of 0.09. The current PB Ratio is 0.09, which is 47% below median its 10-year median of 0.17 and 95.1% below the Drug Manufacturers industry median of 1.86. China SXT Pharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current PB Ratio is 0.09 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
26GF Score
Get the complete analysis for SXTC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTC has been successfully added to your 
